TRIPS and the Life Sciences - Perspectives on Limitations to Patentability
9 Pages Posted: 16 Jun 2017 Last revised: 8 Jul 2017
Date Written: June 15, 2017
This report is based on the material and input that was presented and discussed at the webinar with the title: “Perspectives on limitations to patentability”. The Webinar and the theme where introduced by Prof. Timo Minssen. Then Prof. Nari Lee gave a presentation introducing some of the context and considerations related to TRIPS art 27 and the concept of technological neutrality. Then Dr. Mike Snodin presented some central points form his recent article considering the so-called “Correa Guidelines” and their compatibility with the obligations enshrined in TRIPS art 27. After the introduction and the two presentations, the open discussion turned to questions, comments and considerations of related issues such as the need for alternative incentives, purpose bound product protection, user driven solutions and post-grant instruments.
Keywords: TRIPS agreement, Patents, Correa guidelines, Technological neutrality, non-discrimination, Life science, Pharmaindustry, Biotechnology
Suggested Citation: Suggested Citation